Ticagrelor Can Be an Important Agent in the Treatment of Severe COVID-19 Patients with Myocardial Infarction
- 24 April 2020
- journal article
- letter
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 37 (4), 233
- https://doi.org/10.4274/balkanmedj.galenos.2020.2020.4.100
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive BacteriaJAMA Cardiology, 2019
- Ticagrelor Reduces Thromboinflammatory Markers in Patients With PneumoniaJACC: Basic To Translational Science, 2018
- Tumour Necrosis Factor-alpha and Nuclear Factor-kappa B Gene Variants in SepsisBalkan Medical Journal, 2018
- Ticagrelor – toward more efficient platelet inhibition and beyondTherapeutics and Clinical Risk Management, 2018
- Genomic characterization of recurrent high-grade astroblastomaCancer Genetics, 2016
- Astroblastoma: Report of two cases with unexpected clinical behavior and review of the literatureClinical Neurology and Neurosurgery, 2014
- Cerebral astroblastoma: analysis of six cases and critical review of treatment optionsJournal of Neuro-Oncology, 2009